Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(methylpyridazine piperidine butyloxyphenyl)ethylacetate is a synthetic small molecule belonging to the class of benzoic acid esters. Its chemical formula is C23H31N3O3 and it has a molecular weight of approximately 397.5 g/mol[1][2][3]. The compound is also known by code names R80633 and DB08014, and its structure features a methyl-substituted pyridazine ring linked via a piperidine moiety to a butyloxyphenyl group, which is further esterified with an ethyl group. There are no approved therapeutic indications or clinical trial data available for this compound as of the latest updates; it appears to be an experimental molecule with no established mechanism of action or known pharmacological activity in humans[2]. No information on its developer, manufacturer, or primary indication has been published.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (methylpyridazine piperidine butyloxyphenyl)ethylacetate.